Caren van Roekel

202 Chapter 7 REFERENCES 1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. Epub 2018/09/13. 2. Donadon M, Ribero D, Morris-Stiff G, Abdalla EK, Vauthey JN. New paradigm in the management of liver-only metastases from colorectal cancer. Gastrointest Cancer Res. 2007;1(1):20-7. 3. Network NCC. NCCN Guidelines Version 1.2018 Colon Cancer. 2018 [cited 2019 September 12]; Available from: https:// oncolife.com.ua/doc /nccn/Colon _ Cancer.pdf. 4. Smits MLJ, Dassen MG, Prince JF, Braat A, Beijst C, Bruijnen RCG, et al. The superior predictive value of ( 166 ) Ho-scout compared with (99m)Tc- macroaggregated albumin prior to ( 166 ) Ho-microspheres radioembolization in patients with liver metastases. Eur J Nucl Med Mol Im. 2020;47(4):798-806. Epub 2019/08/11. 5. Reinders MTM, Smits MLJ, van Roekel C, Braat A. Holmium-166 Microsphere Radioembolization of Hepatic Malignancies. Sem Nucl Med. 2019;49(3):237-43. Epub 2019/04/08. 6. Prince JF, van den Bosch M, Nijsen JFW, Smits MLJ, van den Hoven AF, Nikolakopoulos S, et al. Efficacy of radioembolization with ( 166 )Ho- microspheres in salvage patients with liver metastases: a phase 2 study. J Nucl Med. 2018;59(4):582-8. Epub 2017/09/17. 7. Smits MLJ, Nijsen JFW, van den Bosch MAAJ, Lam MGEH, Vente MAD, Mali WPTM, et al. Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study. Lancet Oncol. 2012;13(10):1025-34. 8. van den Hoven AF, Prince JF, Bruijnen RC, Verkooijen HM, Krijger GC, Lam MG, et al. Surefire infusion system versus standard microcatheter use during holmium-166 radioembolization: study protocol for a randomized controlled trial. Trials. 2016;17(1):520. Epub 2016/10/27. 9. Braat AJAT, Bruijnen RCG, van Rooij R, Braat MNGJA, Wessels FJ, van Leeuwaarde RS, et al. Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single- centre, single-arm, open-label, phase 2 study. Lancet Oncol. 2020;21(4):561-70.